Chromatin lysine acylation: On the path to chromatin homeostasis and genome integrity

IF 4.5 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2024-08-18 DOI:10.1111/cas.16321

Feng Chen, Xingkai He, Wenchao Xu, Linmin Zhou, Qi Liu, Weicheng Chen, Wei-Guo Zhu, Jun Zhang

{"title":"Chromatin lysine acylation: On the path to chromatin homeostasis and genome integrity","authors":"Feng Chen, Xingkai He, Wenchao Xu, Linmin Zhou, Qi Liu, Weicheng Chen, Wei-Guo Zhu, Jun Zhang","doi":"10.1111/cas.16321","DOIUrl":null,"url":null,"abstract":"<p>The fundamental role of cells in safeguarding the genome's integrity against DNA double-strand breaks (DSBs) is crucial for maintaining chromatin homeostasis and the overall genomic stability. Aberrant responses to DNA damage, known as DNA damage responses (DDRs), can result in genomic instability and contribute significantly to tumorigenesis. Unraveling the intricate mechanisms underlying DDRs following severe damage holds the key to identify therapeutic targets for cancer. Chromatin lysine acylation, encompassing diverse modifications such as acetylation, lactylation, crotonylation, succinylation, malonylation, glutarylation, propionylation, and butyrylation, has been extensively studied in the context of DDRs and chromatin homeostasis. Here, we delve into the modifying enzymes and the pivotal roles of lysine acylation and their crosstalk in maintaining chromatin homeostasis and genome integrity in response to DDRs. Moreover, we offer a comprehensive perspective and overview of the latest insights, driven primarily by chromatin acylation modification and associated regulators.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 11","pages":"3506-3519"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16321","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The fundamental role of cells in safeguarding the genome's integrity against DNA double-strand breaks (DSBs) is crucial for maintaining chromatin homeostasis and the overall genomic stability. Aberrant responses to DNA damage, known as DNA damage responses (DDRs), can result in genomic instability and contribute significantly to tumorigenesis. Unraveling the intricate mechanisms underlying DDRs following severe damage holds the key to identify therapeutic targets for cancer. Chromatin lysine acylation, encompassing diverse modifications such as acetylation, lactylation, crotonylation, succinylation, malonylation, glutarylation, propionylation, and butyrylation, has been extensively studied in the context of DDRs and chromatin homeostasis. Here, we delve into the modifying enzymes and the pivotal roles of lysine acylation and their crosstalk in maintaining chromatin homeostasis and genome integrity in response to DDRs. Moreover, we offer a comprehensive perspective and overview of the latest insights, driven primarily by chromatin acylation modification and associated regulators.

Abstract Image

查看原文本刊更多论文

染色质赖氨酸酰化：染色质平衡与基因组完整性之路

细胞在保护基因组完整性、防止 DNA 双链断裂（DSB）方面发挥着基础性作用，这对维持染色质平衡和基因组整体稳定性至关重要。对DNA损伤的异常反应，即DNA损伤反应（DDR），可导致基因组不稳定，并在很大程度上导致肿瘤发生。揭示严重损伤后 DDRs 的复杂机制是确定癌症治疗靶点的关键。染色质赖氨酸酰化包括乙酰化、乳酰化、巴豆酰化、琥珀酰化、丙二酰化、谷氨酰化、丙酰化和丁酰化等多种修饰，在 DDRs 和染色质稳态的背景下已被广泛研究。在这里，我们深入研究了赖氨酸酰化的修饰酶和关键作用，以及它们在应对 DDRs 过程中维持染色质稳态和基因组完整性的相互关系。此外，我们还从全面的角度概述了主要由染色质酰化修饰和相关调节因子驱动的最新见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.